Advertisement
Screener

PUMA BIOTECHNOLOGY, INC. (PBYI) Licenses Revenue (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

PUMA BIOTECHNOLOGY, INC. Licenses Revenue (Deprecated 2018-01-31)

PUMA BIOTECHNOLOGY, INC. (PBYI) reported Licenses Revenue (Deprecated 2018-01-31) of $30.50 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.

Discontinued › Income Statement › Other Income

us-gaap:LicensesRevenue · last filed 2018-05-10

  • PUMA BIOTECHNOLOGY, INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $30.50M.
  • PUMA BIOTECHNOLOGY, INC. licenses revenue (deprecated 2018-01-31) for fiscal 2017 was $1.50M.
Period endLicenses Revenue (Deprecated 2018-01-31) 3 monthLicenses Revenue (Deprecated 2018-01-31) 12 month
2018-03-31$30.50M
10-Q · filed 2018-05-10
2017-12-31$1.50M
10-K · filed 2018-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARVINAS, INC. (ARVN)United States$0.510B58.38
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Evolus, Inc. (EOLS)United States$0.519B-13.32
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76